Determine the necessary mass, volume, or concentration for preparing a solution.
This is a demo store. No orders will be fulfilled.
| SKU | Size | Availability |
Price | Qty |
|---|---|---|---|---|
|
S414206-5mg
|
5mg |
5
|
$15.90
|
|
|
S414206-25mg
|
25mg |
5
|
$33.90
|
|
|
S414206-100mg
|
100mg |
5
|
$99.90
|
|
|
S414206-250mg
|
250mg |
5
|
$169.90
|
|
|
S414206-1g
|
1g |
3
|
$436.90
|
|
Ras Inhibitors
| Synonyms | 2252403-56-6 | BA172505 | BDBM50514402 | AMG 510 pound>>AMG-510 | BRD-K03981224-001-02-9 | Congestion | SCHEMBL3491 | Kras G12C inhibitor 9 | PYRILAMINE MALEATE [VANDF] | (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)- |
|---|---|
| Specifications & Purity | ≥98% |
| Biochemical and Physiological Mechanisms | Sotorasib (AMG510) is a potent KRAS G12C covalent inhibitor with potential antineoplastic activity.This AMG510 is a chiral compound. |
| Storage Temp | Store at -20°C,Argon charged |
| Shipped In |
Ice chest + Ice pads This product requires cold chain shipping. Ground and other economy services are not available. |
| Product Description |
Information Sotorasib (AMG510) Sotorasib (AMG510) is a potent KRAS G12C covalent inhibitor with potential antineoplastic activity. This AMG510 is a chiral compound. Targets K-Ras(G12C) In vitro AMG 510 inhibits SOS1-catalyzed nucleotide exchange of recombinant mutant KRAS (G12C/C118A) but had minimal effect on KRAS (C118A). AMG 510 also selectively impairs the viability of KRAS p.G12C mutant lines but does not affect cell lines with other KRAS mutations. In vivo In preclinical tumor models, AMG 510 rapidly and irreversibly binds to KRAS (G12C), providing durable suppression of the mitogen-activated protein kinase (MAPK) signaling pathway. Dosed orally (once daily) as a single agent, AMG 510 is capable of inducing tumor regression in mouse models of KRASG12C cancer. |
Taxonomy Tree
| Kingdom | Organic compounds |
|---|---|
| Superclass | Organoheterocyclic compounds |
| Class | Pyridines and derivatives |
| Subclass | Phenylpyridines |
| Intermediate Tree Nodes | Not available |
| Direct Parent | Phenylpyridines |
| Alternative Parents | N-arylpiperazines Pyrido[2,3-d]pyrimidines M-fluorophenols Dialkylarylamines Pyrimidones Methylpyridines Fluorobenzenes Aminopyrimidines and derivatives 1-hydroxy-4-unsubstituted benzenoids 1-hydroxy-2-unsubstituted benzenoids Imidolactams Aryl fluorides Tertiary carboxylic acid amides Heteroaromatic compounds Acrylic acids and derivatives Azacyclic compounds Organopnictogen compounds Organofluorides Organic oxides Hydrocarbon derivatives Carbonyl compounds |
| Molecular Framework | Aromatic heteropolycyclic compounds |
| Substituents | N-arylpiperazine - 2-phenylpyridine - Pyrido[2,3-d]pyrimidine - Pyridopyrimidine - Dialkylarylamine - 3-fluorophenol - 3-halophenol - 1-hydroxy-4-unsubstituted benzenoid - 1-hydroxy-2-unsubstituted benzenoid - Methylpyridine - Pyrimidone - Phenol - Halobenzene - Fluorobenzene - Aminopyrimidine - Imidolactam - Benzenoid - Pyrimidine - Piperazine - 1,4-diazinane - Monocyclic benzene moiety - Aryl halide - Aryl fluoride - Acrylic acid or derivatives - Heteroaromatic compound - Tertiary carboxylic acid amide - Carboxamide group - Azacycle - Carboxylic acid derivative - Organic nitrogen compound - Organic oxygen compound - Organopnictogen compound - Organic oxide - Hydrocarbon derivative - Organooxygen compound - Organonitrogen compound - Organofluoride - Organohalogen compound - Carbonyl group - Aromatic heteropolycyclic compound |
| Description | This compound belongs to the class of organic compounds known as phenylpyridines. These are polycyclic aromatic compounds containing a benzene ring linked to a pyridine ring through a CC or CN bond. |
| External Descriptors | Not available |
|
|
|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
| Pubchem Sid | 504773485 |
|---|---|
| Pubchem Sid Url | https://pubchem.ncbi.nlm.nih.gov/substance/504773485 |
| IUPAC Name | 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one |
| INCHI | InChI=1S/C30H30F2N6O3/c1-6-23(40)36-12-13-37(18(5)15-36)28-19-14-21(32)26(24-20(31)8-7-9-22(24)39)34-29(19)38(30(41)35-28)27-17(4)10-11-33-25(27)16(2)3/h6-11,14,16,18,39H,1,12-13,15H2,2-5H3/t18-/m0/s1 |
| InChIKey | NXQKSXLFSAEQCZ-SFHVURJKSA-N |
| Smiles | CC1CN(CCN1C2=NC(=O)N(C3=NC(=C(C=C32)F)C4=C(C=CC=C4F)O)C5=C(C=CN=C5C(C)C)C)C(=O)C=C |
| Isomeric SMILES | C[C@H]1CN(CCN1C2=NC(=O)N(C3=NC(=C(C=C32)F)C4=C(C=CC=C4F)O)C5=C(C=CN=C5C(C)C)C)C(=O)C=C |
| PubChem CID | 137278711 |
| Molecular Weight | 560.59 |
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
| Certificate of Analysis | Apr 03, 2025 | S414206 | |
| Certificate of Analysis | Mar 05, 2025 | S414206 | |
| Certificate of Analysis | Mar 05, 2025 | S414206 | |
| Certificate of Analysis | Jul 06, 2023 | S414206 | |
| Certificate of Analysis | Jul 06, 2023 | S414206 | |
| Certificate of Analysis | Jul 06, 2023 | S414206 | |
| Certificate of Analysis | Jul 06, 2023 | S414206 | |
| Certificate of Analysis | Jul 06, 2023 | S414206 | |
| Certificate of Analysis | Jul 06, 2023 | S414206 | |
| Certificate of Analysis | Jul 06, 2023 | S414206 | |
| Certificate of Analysis | Jul 06, 2023 | S414206 | |
| Certificate of Analysis | Jul 06, 2023 | S414206 | |
| Certificate of Analysis | Jul 06, 2023 | S414206 | |
| Certificate of Analysis | Jun 05, 2022 | S414206 | |
| Certificate of Analysis | Jun 05, 2022 | S414206 | |
| Certificate of Analysis | Jun 05, 2022 | S414206 |
| Solubility | Solubility (25°C) In vitro DMSO: 100 mg/mL (178.38 mM); Ethanol: 8 mg/mL (14.27 mM); Water: Insoluble; |
|---|---|
| Molecular Weight | 560.600 g/mol |
| XLogP3 | 4.000 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 5 |
| Exact Mass | 560.235 Da |
| Monoisotopic Mass | 560.235 Da |
| Topological Polar Surface Area | 102.000 Ų |
| Heavy Atom Count | 41 |
| Formal Charge | 0 |
| Complexity | 1030.000 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| The total count of all stereochemical bonds | 0 |
| Covalently-Bonded Unit Count | 1 |
Starting at $29.90
Starting at $84.90
| 1. Yang Chen, Wenzhe Xu, Hao Jin, Mengsi Zhang, Shuwei Liu, Yi Liu, Hao Zhang. (2024) Nutritional Glutamine-Modified Iron-Delivery System with Enhanced Endocytosis for Ferroptosis Therapy of Pancreatic Tumors. ACS Nano, 18 (46): (31846-31868). |